Article Text

other Versions

PDF
Intrathecal injection of tigecycline in treatment of multidrug-resistant Acinetobacter baumannii meningitis: a case report
  1. Lijiang Wang,
  2. Jirong Zhang,
  3. Xiaoqing Yu,
  4. Jiuzhong Wang,
  5. Lifeng Cheng,
  6. Shuzhen Hu,
  7. Guangliang Han
  1. Department of Neurosurgery, Shengli Oilfield Central Hospital of Binzhou Medical University, Dongying, Shandong, China
  1. Correspondence to
    Lijiang Wang, Department of Neurosurgery, Shengli Oilfield Central Hospital of Binzhou Medical University, Dongying, Shandong 257034, China; wanglijiang200703{at}163.com

Abstract

The ubiquitous Acinetobacter baumannii is an important and troublesome pathogen of nosocomial infection. Multidrug-resistant A baumannii meningitis is very difficult to treat, usually with high mortality. The disease is generally associated with craniotomy, but rarely with lumbar puncture. However, in our case, a 45-year-old male construction worker suffered multidrug-resistant A baumannii meningitis associated with lumbar puncture. The patient responded poorly to the initial treatment with an intravenous infusion of tigecycline. However, later treatment with an intrathecal injection of tigecycline (concentration 1 mg/mL) at a dose of 10 mg every 12 hours proved to be highly efficacious. Thus, intrathecal injection of tigecycline should be seriously considered as a treatment for multidrug-resistant A baumannii meningitis.

  • tigecycline
  • injection
  • multidrug-resistant
  • acinetobacter baumannii
  • meningitis

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.